Professor Sir Rory Collins, the austere director of the institute in Oxford that produce much of the evidence supporting the increasing use of cholesterol –lowering statins, is in hot water once more. Last week he declared that he intended to investigate himself.
Post Tagged with: "PCSK9 inhibitors"
An era is coming to an end. Statins, the world’s most widely prescribed and profitable drugs, have, with the exception Crestor (rosuvastatin), all come off patent and their price has plummeted. Good news for NHS accountants not so good for company profits. (Read more…)